Role of the APP non-amyloidogenic signaling pathway and targeting α-secretase as an alternative drug target for treatment of Alzheimer's diseases

S. Bandyopadhyay, L. E. Goldstein, Debomoy Lahiri, J. T. Rogers

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most prevalent form of dementia, and its effective disease modifying therapies are desperately needed. Promotion of non-amyloidogenic alpha (α)-secretase cleavage of amyloid precursor protein (APP) to release soluble sAPPα, based on the most widely accepted "amyloid model" as a plausible mechanism for AD treatment, is the focus of this review. Modulation of α-secretase or "a disintegrin and metalloprotease (ADaM)"s activity via protein kinase C (PKC), calcium ion (Ca2+), tyrosine kinase (TK), MAP kinase (MAPK), and hormonal signaling, which regulate catabolic processing of APP, are discussed. The inhibition of amyloidogenic processing of APP by the beta (β)-and gamma (γ)-secretase has been considered till now a promising strategy to treat AD. But β- and γ-secretase inhibitors, along with the available therapeutic tools for AD, have side effects. These challenges can be circumvented to certain extent; but activation of sAPPα release appears to be a potential alternative strategy to reduce cerebral amyloidosis. Drug screens have been performed to identify therapeutics for AD, but an effective screening strategy to isolate activators of α-secretase has been rarely reported. Novel reporter-based screens targeted toward APP mRNA 5+ untranslated region (UTR), allowed by counter-screens to detect α-secretase stimulators, could be important in detecting compounds to promote sAPPα release and reduce amyloid beta (Aβ) buildup. The primary inflammatory cytokine interleukin-1, which stimulates APP 5′UTR-directed translation of cell-associated APP, enhances processing to sAPPα in astrocytes and co-activates ADAM-10/ADAM-17 through MAPK signaling; thus illustrating a novel pathway that could serve as therapeutic model for AD.

Original languageEnglish
Pages (from-to)2848-2864
Number of pages17
JournalCurrent Medicinal Chemistry
Volume14
Issue number27
DOIs
StatePublished - Nov 2007

Fingerprint

Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
Alzheimer Disease
Pharmaceutical Preparations
Amyloid
Processing
Disintegrins
5' Untranslated Regions
Mitogen-Activated Protein Kinase Kinases
Metalloproteases
Therapeutics
Interleukin-1
Astrocytes
Protein-Tyrosine Kinases
Protein Kinase C
Dementia
Screening
Phosphotransferases
Chemical activation
Modulation

Keywords

  • ADAM activators
  • APP proteolysis
  • Drug screens
  • Interleukin-1
  • Signaling
  • Soluble sAPPα

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Role of the APP non-amyloidogenic signaling pathway and targeting α-secretase as an alternative drug target for treatment of Alzheimer's diseases. / Bandyopadhyay, S.; Goldstein, L. E.; Lahiri, Debomoy; Rogers, J. T.

In: Current Medicinal Chemistry, Vol. 14, No. 27, 11.2007, p. 2848-2864.

Research output: Contribution to journalArticle

@article{6b91ab83f86443bf9c87ed6b71983f7d,
title = "Role of the APP non-amyloidogenic signaling pathway and targeting α-secretase as an alternative drug target for treatment of Alzheimer's diseases",
abstract = "Alzheimer's disease (AD) is the most prevalent form of dementia, and its effective disease modifying therapies are desperately needed. Promotion of non-amyloidogenic alpha (α)-secretase cleavage of amyloid precursor protein (APP) to release soluble sAPPα, based on the most widely accepted {"}amyloid model{"} as a plausible mechanism for AD treatment, is the focus of this review. Modulation of α-secretase or {"}a disintegrin and metalloprotease (ADaM){"}s activity via protein kinase C (PKC), calcium ion (Ca2+), tyrosine kinase (TK), MAP kinase (MAPK), and hormonal signaling, which regulate catabolic processing of APP, are discussed. The inhibition of amyloidogenic processing of APP by the beta (β)-and gamma (γ)-secretase has been considered till now a promising strategy to treat AD. But β- and γ-secretase inhibitors, along with the available therapeutic tools for AD, have side effects. These challenges can be circumvented to certain extent; but activation of sAPPα release appears to be a potential alternative strategy to reduce cerebral amyloidosis. Drug screens have been performed to identify therapeutics for AD, but an effective screening strategy to isolate activators of α-secretase has been rarely reported. Novel reporter-based screens targeted toward APP mRNA 5+ untranslated region (UTR), allowed by counter-screens to detect α-secretase stimulators, could be important in detecting compounds to promote sAPPα release and reduce amyloid beta (Aβ) buildup. The primary inflammatory cytokine interleukin-1, which stimulates APP 5′UTR-directed translation of cell-associated APP, enhances processing to sAPPα in astrocytes and co-activates ADAM-10/ADAM-17 through MAPK signaling; thus illustrating a novel pathway that could serve as therapeutic model for AD.",
keywords = "ADAM activators, APP proteolysis, Drug screens, Interleukin-1, Signaling, Soluble sAPPα",
author = "S. Bandyopadhyay and Goldstein, {L. E.} and Debomoy Lahiri and Rogers, {J. T.}",
year = "2007",
month = "11",
doi = "10.2174/092986707782360060",
language = "English",
volume = "14",
pages = "2848--2864",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "27",

}

TY - JOUR

T1 - Role of the APP non-amyloidogenic signaling pathway and targeting α-secretase as an alternative drug target for treatment of Alzheimer's diseases

AU - Bandyopadhyay, S.

AU - Goldstein, L. E.

AU - Lahiri, Debomoy

AU - Rogers, J. T.

PY - 2007/11

Y1 - 2007/11

N2 - Alzheimer's disease (AD) is the most prevalent form of dementia, and its effective disease modifying therapies are desperately needed. Promotion of non-amyloidogenic alpha (α)-secretase cleavage of amyloid precursor protein (APP) to release soluble sAPPα, based on the most widely accepted "amyloid model" as a plausible mechanism for AD treatment, is the focus of this review. Modulation of α-secretase or "a disintegrin and metalloprotease (ADaM)"s activity via protein kinase C (PKC), calcium ion (Ca2+), tyrosine kinase (TK), MAP kinase (MAPK), and hormonal signaling, which regulate catabolic processing of APP, are discussed. The inhibition of amyloidogenic processing of APP by the beta (β)-and gamma (γ)-secretase has been considered till now a promising strategy to treat AD. But β- and γ-secretase inhibitors, along with the available therapeutic tools for AD, have side effects. These challenges can be circumvented to certain extent; but activation of sAPPα release appears to be a potential alternative strategy to reduce cerebral amyloidosis. Drug screens have been performed to identify therapeutics for AD, but an effective screening strategy to isolate activators of α-secretase has been rarely reported. Novel reporter-based screens targeted toward APP mRNA 5+ untranslated region (UTR), allowed by counter-screens to detect α-secretase stimulators, could be important in detecting compounds to promote sAPPα release and reduce amyloid beta (Aβ) buildup. The primary inflammatory cytokine interleukin-1, which stimulates APP 5′UTR-directed translation of cell-associated APP, enhances processing to sAPPα in astrocytes and co-activates ADAM-10/ADAM-17 through MAPK signaling; thus illustrating a novel pathway that could serve as therapeutic model for AD.

AB - Alzheimer's disease (AD) is the most prevalent form of dementia, and its effective disease modifying therapies are desperately needed. Promotion of non-amyloidogenic alpha (α)-secretase cleavage of amyloid precursor protein (APP) to release soluble sAPPα, based on the most widely accepted "amyloid model" as a plausible mechanism for AD treatment, is the focus of this review. Modulation of α-secretase or "a disintegrin and metalloprotease (ADaM)"s activity via protein kinase C (PKC), calcium ion (Ca2+), tyrosine kinase (TK), MAP kinase (MAPK), and hormonal signaling, which regulate catabolic processing of APP, are discussed. The inhibition of amyloidogenic processing of APP by the beta (β)-and gamma (γ)-secretase has been considered till now a promising strategy to treat AD. But β- and γ-secretase inhibitors, along with the available therapeutic tools for AD, have side effects. These challenges can be circumvented to certain extent; but activation of sAPPα release appears to be a potential alternative strategy to reduce cerebral amyloidosis. Drug screens have been performed to identify therapeutics for AD, but an effective screening strategy to isolate activators of α-secretase has been rarely reported. Novel reporter-based screens targeted toward APP mRNA 5+ untranslated region (UTR), allowed by counter-screens to detect α-secretase stimulators, could be important in detecting compounds to promote sAPPα release and reduce amyloid beta (Aβ) buildup. The primary inflammatory cytokine interleukin-1, which stimulates APP 5′UTR-directed translation of cell-associated APP, enhances processing to sAPPα in astrocytes and co-activates ADAM-10/ADAM-17 through MAPK signaling; thus illustrating a novel pathway that could serve as therapeutic model for AD.

KW - ADAM activators

KW - APP proteolysis

KW - Drug screens

KW - Interleukin-1

KW - Signaling

KW - Soluble sAPPα

UR - http://www.scopus.com/inward/record.url?scp=36749037180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749037180&partnerID=8YFLogxK

U2 - 10.2174/092986707782360060

DO - 10.2174/092986707782360060

M3 - Article

C2 - 18045131

AN - SCOPUS:36749037180

VL - 14

SP - 2848

EP - 2864

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 27

ER -